Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation LAA 2017

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Gregg W. Stone

July 22, 2017

Presentation TCT 2014

Fundamentals for Creating of a Successful Multidisciplinary LAA Occlusion Program

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Michael J. Rinaldi

September 15, 2014

Presentation TCT 2014

AF Ablation: Stand-Alone and in Conjunction with LAA Closure

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

Presentation TCT 2014

LARIAT Experience in Patients Contraindicated to Anticoagulation

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Sameer Gafoor

September 15, 2014

Presentation TCT 2014

Transpericardial LAA Closure: Multicenter Results with the LARIAT

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Matthew J. Price

September 15, 2014

Presentation TCT 2014

Results with the Amplatzer Cardiac Plug (ACP)

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Reda Ibrahim

September 15, 2014

Presentation TCT 2014

Watchman II: PROTECT-AF/PREVAIL Meta-analysis and Implications

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, David R. Holmes Jr.

September 15, 2014

Presentation TCT 2014

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

Presentation LAA 2014

Safety and Efficacy of the WAVECREST: First-in-Human Experiences and Future Trials

Presenter: Gregg W. Stone

July 19, 2014

Presentation LAA 2014

The Coherex WAVECREST: LAA Occluder

Presenter: Gregg W. Stone

July 17, 2014

Presentation

Post ACC Wrap-up: PREVAIL and PARTNER II

Presenter: Gregg W. Stone

March 13, 2013

Presentation TCT 2012

The New Anticoagulants: A Meaningful Step Forward?

Presenter: Gregg Stone

October 23, 2012

Presentation TVT 2012

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

Presenter: Gregg Stone

June 05, 2012

Advertisement

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Fundamentals for Creating of a Successful Multidisciplinary LAA Occlusion Program

AF Ablation: Stand-Alone and in Conjunction with LAA Closure

LARIAT Experience in Patients Contraindicated to Anticoagulation

Transpericardial LAA Closure: Multicenter Results with the LARIAT

Results with the Amplatzer Cardiac Plug (ACP)

Watchman II: PROTECT-AF/PREVAIL Meta-analysis and Implications

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

Safety and Efficacy of the WAVECREST: First-in-Human Experiences and Future Trials

The Coherex WAVECREST: LAA Occluder

Post ACC Wrap-up: PREVAIL and PARTNER II

The New Anticoagulants: A Meaningful Step Forward?

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content